- QMRO Home
- Barts Cancer Institute
- Centre for Molecular Oncology
- Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial.
Browse
Administrators only